Late-stage study suggests Merck’s Keytruda is a promising treatment candidate in newly diagnosed patients with locally advanced cervical cancer, inducing better progression-free survival.
https://www.pharmalive.com/wp-content/uploads/2020/12/Merck-Strikes-1B-Deal-to-Leverage-Januxs-T-Cell-Engager-Program-Against-Cancer-BioSpace-12-18-20.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-07-19 10:19:202023-07-19 10:41:56Phase III Data show Keytruda’s promise in earlier-stage cervical cancer
